These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 26789901)

  • 1. Cytomegalovirus Retinitis in a Patient Who Received Ruxolitinib.
    von Hofsten J; Johnsson Forsberg M; Zetterberg M
    N Engl J Med; 2016 Jan; 374(3):296-7. PubMed ID: 26789901
    [No Abstract]   [Full Text] [Related]  

  • 2. Development of extramedullary sites of leukaemia during ruxolitinib therapy for myelofibrosis.
    Kremyanskaya M; Mascarenhas J; Rampal R; Hoffman R
    Br J Haematol; 2014 Oct; 167(1):144-6. PubMed ID: 24862179
    [No Abstract]   [Full Text] [Related]  

  • 3. Ruxolitinib: the first agent approved for myelofibrosis.
    Verstovsek S
    Clin Adv Hematol Oncol; 2012 Feb; 10(2):111-3. PubMed ID: 22402352
    [No Abstract]   [Full Text] [Related]  

  • 4. Pulmonary tuberculosis reactivation following ruxolitinib treatment in a patient with primary myelofibrosis.
    Chen YH; Lee CH; Pei SN
    Leuk Lymphoma; 2015 May; 56(5):1528-9. PubMed ID: 25213182
    [No Abstract]   [Full Text] [Related]  

  • 5. Ruxolitinib is a potent immunosuppressive compound: is it time for anti-infective prophylaxis?
    Heine A; Brossart P; Wolf D
    Blood; 2013 Nov; 122(23):3843-4. PubMed ID: 24288410
    [No Abstract]   [Full Text] [Related]  

  • 6. Pneumocystis jiroveci pneumonitis complicating ruxolitinib therapy.
    Lee SC; Feenstra J; Georghiou PR
    BMJ Case Rep; 2014 Jun; 2014():. PubMed ID: 24891492
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term Effects of the Janus Kinase 1/2 Inhibitor Ruxolitinib on Pulmonary Hypertension and the Cardiac Function in a Patient with Myelofibrosis.
    Miyawaki H; Kioka H; Sato K; Kurashige M; Ozawa T; Shibayama H; Hikoso S; Morii E; Yamauchi-Takihara K; Sakata Y
    Intern Med; 2020 Jan; 59(2):229-233. PubMed ID: 31534088
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Ruxolitinib prescription in myelofibrosis].
    Lemal R; Robin M; Ravinet A; Cacheux V; Guièze R; Bay JO
    Bull Cancer; 2013 Sep; 100(9):897-902. PubMed ID: 23985569
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term outcome of treatment with ruxolitinib in myelofibrosis.
    Tefferi A; Litzow MR; Pardanani A
    N Engl J Med; 2011 Oct; 365(15):1455-7. PubMed ID: 21995409
    [No Abstract]   [Full Text] [Related]  

  • 10. An opportunistic infection associated with ruxolitinib, a novel janus kinase 1,2 inhibitor.
    Wysham NG; Sullivan DR; Allada G
    Chest; 2013 May; 143(5):1478-1479. PubMed ID: 23648912
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sustained-release ruxolitinib: Findings from a phase 1 study in healthy subjects and a phase 2 study in patients with myelofibrosis.
    Verstovsek S; Yeleswaram S; Hou K; Chen X; Erickson-Viitanen S
    Hematol Oncol; 2018 Oct; 36(4):701-708. PubMed ID: 30105794
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug-associated skin lesions in a patient with myelofibrosis receiving ruxolitinib.
    Fournier JB; Cummings F; Cannella J; Breen C; Zhou L; Iwamoto S
    Dermatol Online J; 2014 Oct; 20(10):. PubMed ID: 25526003
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disseminated tuberculosis associated with ruxolitinib.
    Hopman RK; Lawrence SJ; Oh ST
    Leukemia; 2014 Aug; 28(8):1750-1. PubMed ID: 24625550
    [No Abstract]   [Full Text] [Related]  

  • 14. Progressive multifocal leukoencephalopathy associated with ruxolitinib.
    Wathes R; Moule S; Milojkovic D
    N Engl J Med; 2013 Jul; 369(2):197-8. PubMed ID: 23841743
    [No Abstract]   [Full Text] [Related]  

  • 15. JAK inhibition with ruxolitinib as pretreatment for allogeneic stem cell transplantation in primary or post-ET/PV myelofibrosis.
    Stübig T; Alchalby H; Ditschkowski M; Wolf D; Wulf G; Zabelina T; Wolschke C; Ayuk F; Kröger N
    Leukemia; 2014 Aug; 28(8):1736-8. PubMed ID: 24569777
    [No Abstract]   [Full Text] [Related]  

  • 16. Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis.
    Palandri F; Palumbo GA; Elli EM; Polverelli N; Benevolo G; Martino B; Abruzzese E; Tiribelli M; Tieghi A; Latagliata R; Cavazzini F; Bergamaschi M; Binotto G; Crugnola M; Isidori A; Caocci G; Heidel F; Pugliese N; Bosi C; Bartoletti D; Auteri G; Cattaneo D; Scaffidi L; Trawinska MM; Stella R; Ciantia F; Pane F; Cuneo A; Krampera M; Semenzato G; Lemoli RM; Iurlo A; Vianelli N; Cavo M; Breccia M; Bonifacio M
    Blood Cancer J; 2021 Jan; 11(1):4. PubMed ID: 33414394
    [No Abstract]   [Full Text] [Related]  

  • 17. Ruxolitinib for myelofibrosis--an update of its clinical effects.
    Kantarjian HM; Silver RT; Komrokji RS; Mesa RA; Tacke R; Harrison CN
    Clin Lymphoma Myeloma Leuk; 2013 Dec; 13(6):638-45. PubMed ID: 24238036
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Klebsiella pneumoniae primary liver abscess associated with ruxolitinib.
    Kusano Y; Terui Y; Ueda K; Hatake K
    Ann Hematol; 2016 Sep; 95(9):1561-2. PubMed ID: 27259987
    [No Abstract]   [Full Text] [Related]  

  • 19. Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I.
    Verstovsek S; Mesa RA; Gotlib J; Levy RS; Gupta V; DiPersio JF; Catalano JV; Deininger MW; Miller CB; Silver RT; Talpaz M; Winton EF; Harvey JH; Arcasoy MO; Hexner EO; Lyons RM; Raza A; Vaddi K; Sun W; Peng W; Sandor V; Kantarjian H;
    Haematologica; 2015 Apr; 100(4):479-88. PubMed ID: 25616577
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial.
    Al-Ali HK; Griesshammer M; le Coutre P; Waller CF; Liberati AM; Schafhausen P; Tavares R; Giraldo P; Foltz L; Raanani P; Gupta V; Tannir B; Ronco JP; Ghosh J; Martino B; Vannucchi AM
    Haematologica; 2016 Sep; 101(9):1065-73. PubMed ID: 27247324
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.